Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Buccolam (midazolam) in acute seizures in adults
- Padcev (enfortumab vedotin) in the treatment of patients with urothelial cancer
- Keytruda (pembrolizumab) in the treatment of patients with urothelial cancer
- Tecartus (brexucabtagene autoleucel) in the treatment of patients with B-cell lymphomas
- Leqvio (inclisiran) in the treatment of patients with lipid disorders
- Repatha (evolocumab) in the treatment of patients with lipid disorders
- Praluent (alirocumab) in the treatment of patients with lipid disorders
- Trodelvy (sacituzumab govitecan) in the treatment of breast cancer patients
- Tecartus (brexucabtagene autoleucel) in the treatment of patients with B-cell lymphomas
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
